DR.GOPAL KUNDU'S LIST OF PUBLICATIONS

Kundu GC and Sinha NK: Purification and characterization of proteinase inhibitor from artocarpus integrifolia seeds. Phytochemistry 28:725-728, 1989.

  2.       Sen S, Kundu GC, Castel J, Mekhail N, Misono KS and Healy B:  Myotrophin: Purification of a novel peptide from spontaneously hypertensive rat heart that influences myocardial growth. J. Biol. Chem. 265 (27): 16635-16643, 1990.

3.         Kundu GC and Misono KS: Affinity labeling of endothelin receptors in bovine and rat lung membranes by N^Î9- azidobenzoyl-¹²⁵ I-endothelin-1. Mol. and Cell. Endocrinology 79: 85-92, 1991.

4.         Kundu GC and Wilson IB: Identification of endothelin converting enzyme in bovine lung membranes using a new fluorogenic substrate. Life Sciences 50(13): 965-970, 1992.

5.         Kundu GC and Wilson IB : Endothelin converting enzyme: the binding of metal ions. Int. J. Peptide and Protein Res. 42(1): 64-67, 1993.

6.         Kundu GC, Schullek JR and Wilson IB: The alkylating properties of chlorambucil. Pharmacol. Biochem. Behav. 49(3): 621-624, 1994.

7.         Kundu GC, Ji I, McCormick DJ, and Ji TH: Photoaffinity labeling of the lutropin receptor with synthetic peptide for carboxyl terminus of the human choriogonadotropin a subunit. J. Biol. Chem. 271(19): 11063-11066, 1996.

8.         Kundu GC, Mantile G, Miele L, Cordela-Miele E and Mukherjee AB: Recombinant human uteroglobin suppresses cellular invasiveness via a novel class of high-affinity cell surface binding site. Proc. Natl. Acad. Sci. USA 93: 2915-2919, 1996.

9.         Kundu GC and Mukherjee AB: Evidence that porcine pancreatic phospholipase A₂ via its high-affinity receptor stimulates extracellular matrix invasion by normal and cancer cells. J. Biol. Chem. 272(04), 2346-2353, 1997.

10.       Shanmugam V, Chackalaparampil I, Kundu GC, Mukherjee AB and Mukherjee BB: Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Biochemistry 36(19), 5729-5738, 1997.

11.       Zhang Z, Kundu GC, Yuan C-J, Ward JM, Lee EJ, DeMayo F, Westphal H and Mukherjee AB: Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin. Science 276,1408-1412, 1997.

12.       Kundu GC, Panda D, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC, Seides S, Rosenberg J, Stark K and Mukherjee AB: Potential roles of osteopontin and a_vb₃ integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. USA 94, 9308-9313, 1997.

13.       Phang T, Kundu GC, Hong S, Ji I and Ji TH: The amino terminal region of the luteinizing hormone/choriogonadotropin receptor contacts both subunits of human choriogonadotropin: II Photoaffinity labeling. J. Biol. Chem. 273(22), 13841-13847, 1998.

14.         Kundu GC, Mandal A, Zhang Z, Mantile-Selvaggi G and Mukherjee AB: Uteroglobin suppresses extracellular matrix invasion by normal and cancer cells that express the high affinity UG-binding proteins. J. Biol. Chem. 273 (35), 22819-22824, 1998.

15.         Mukherjee AB, Kundu GC, Mandal AK, Pattabiraman N, Yuan C-J and Zhang Z: Uteroglobin(UG): Physiological role in normal glomerular  function, uncovered by targeted disruption of the UG gene in mice.  Am. J. Kid. Dis. 32 (6), 1106-1120, 1998.

16.        Kundu GC, Zhang Z, Panda D, Mandal A.K., Mantile-Selvaggi Peri A, Yuan C-J and Mukherjee AB: Loss of transformed phenotype in cancer cells by over  expression of  uteroglobin gene. Proc. Natl. Acad. Sci.  USA  96, 3963-3968, 1999.

           

17.    Mukherjee AB, Kundu GC, Mantile-Selvaggi G, Yuan C-J, Mandal AK, Chattopadhyay S, Zhang F, Pattabiraman N and Zhang Z: Uteroglobin: A novel cytokine? Cell Mol Life Sci. 55(5), 771-87, 1999.

18.         Kundu GC, Zheng F, Zhang Z, Ward JM, DeMayo F, Mukherjee AB: An essential role of uteroglobin in preventing immunoglobulin A-nephropathy in mice. Nature Medicine 5(9), 1018-1025, 1999.

19.       Zheng F, Kundu GC, Zhang Z, Mukherjee AB, Ward J and  DeMayo F: Identical glomerulopathy in two different mouse models of uteroglobin deficiency. Am. J. Kid.Dis. 35(2), 362-363, 2000

                       

20.       Zhang Z, Kundu GC, Zheng F, Yuan C-J, Lee E, Westphal H, Ward J, DeMayo F

and Mukherjee AB: Insight into the physiological function(s) of uteroglobin by gene knockout and antisense-transgenic approaches. Annals of the New York Academy of Sciences. 923, 210-233, 2000.

21.       Choudhury B, Mantile-Selvaggi G, Kundu GC, Miele L, Cordella-Miele E, Zhang Z, Mukherjee AB: Amino acid residues in alpha-helix-3 of human uteroglobin are critical for phospholopase A2 inhibitory activity. Annals of the New York Academy of Sciences. 923, 307--311, 2000.

22.       Kundu GC, Zhang Z, Mantile-Selvaggi G, Mandal A, Yuan C-J and Mukherjee AB: Uteroglobin binding proteins: regulation of cellular motility and invasion in normal and cancer cells. Annals of the New York Academy of Sciences. 923, 234-248, 2000.

                                    Publications from NCCS, Pune, India (2001-till date)

23.       Philip S, Bulbule, A and Kundu GC: Osteopontin stimulates tumor growth and activation of pro-matrix metalloproteinase-2 through NF-kappa B mediated induction of membrane type 1-matrix metalloproteinase in murine melanoma cells. J.  Biol. Chem. 276 (48), 44926-44935, 2001.

24.       Annie Bligh SW, Bashall A, Garrud C, McPartlin M, Wardle N, White K, Padhye S, Barve V and Kundu GC: Reaction of (C-(6-aminomethyl-pyridin-2-yl)-methylamine) chloroplatinum (II) with nucleosides and its biological activity. Dalton Transaction, 2, 184-188, 2003.            

25.       Mahabeleshwar GH and Kundu GC: Syk, a protein tyrosine kinase, suppresses the cell motility and NF-kappa B mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3’-kinase activity in breast cancer cells. J. Biol. Chem. 278 (8), 6209-6221, 2003.

26.       Philip S and Kundu GC: Osteopontin induces NF-kappa B mediated promatrix metalloproteinase-2 activation through IKK/IB signaling pathways and curcumin (diferulolylmethane) down regulates these pathways. J. Biol. Chem. 278 (16), 14487-14497, 2003.         

27.       Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S, and Aggarwal BB: Hydrogen peroxide activates NF-B through tyrosine phosphorylation of IB and serine phosphorylation of p65: Evidence for the involvement of IB kinase and Syk protein tyrosine kinase. J. Biol. Chem. 278 (26), 24233-24241, 2003.

28.       Das R, Mahabeleshwar GH and Kundu GC: Osteopontin stimulates cell motility and NF-B mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem. 278 (31), 28593-28606, 2003.

29.      Mahabeleshwar GH and Kundu GC: Tyrosine kinase, p56^lck regulates cell motility and NF-B-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IB following hypoxia/reoxygenation. J. Biol. Chem. 278 (52), 52598-52612, 2003.

30.      Mahabeleshwar GH, Das R and Kundu GC: Tyrosine kinase, p56^lck-induced cell motility and

    urokinase type plasminogen activator secretion involves activation of   epidermal growth  factor receptor/extracellular signal regulated kinase pathways. J. Biol. Chem. 279 (11), 9733-9742, 2004

31.       Philip S, Bulbule A and Kundu GC: Matrix metalloproteinase-2: mechanism and regulation of NF-B-mediated activation and its role in cell motility and ECM-invasion. Glycoconjugate J. 21, 429-441, 2004.

32.     Das R, Mahabeleshwar GH and Kundu GC: Osteopontin induces AP-1-mediated secretion of

          urokinase type plasminogen activator through c-Src dependent EGF receptor transactivation in

          breast cancer cells. J. Biol. Chem. 279 (12), 11051-11064, 2004.

33.       Rangaswami H, Bulbule A and Kundu GC: Nuclear factor inducing kinase plays crucial role in osteopontin induced MAPK/IKK dependent nuclear factor B-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem. 279 (37), 38921-38935, 2004.

34.       Sandbhor U, Kulkarni P, Padhye S, Kundu GC, Mackenzie G and Pritchard R: Antimelanomal activity of the copper (II) complexes of 1-substituted 5-amino imidazole ligands against B16F10 mouse melanoma cells. Bioorg. Med. Chem. Lett. 14(11), 2877-2882, 2004.

           

35.       Das R, Philip S, Mahabeleshwar GH, Bulbule A and Kundu GC: Osteopontin: it’s role in regulation of cell motility and nuclear factor B-mediated urokinase type plasminogen activator expression. IUBMB Life 57 (6), 441-447, 2005.

                                                                                                                                                                 

36.       Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends in Cell Biol. 16 (2), 79-87, 2006.

37.       Chakraborty G, Rangaswami R, Jain S, and Kundu GC: Hypoxia regulates crosstalk

between Syk and Lck leading to breast cancer progression and angiogenesis. J. Biol. Chem. 281 (16), 11322-11331, 2006.

38.       Jain S, Chakraborty G and Kundu GC: The Crucial Role of cyclooxygenase-2 in osteopontin-induced PKCα/c-Src/IKKα/β dependent prostate tumor progression and angiogenesis. Cancer Res. 66 (13), 6638-6648, 2006

39.       Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V and Kundu GC: The multifaceted roles of Osteopontin in cell signaling, tumor progression and angiogenesis. Curr. Mol. Med. 6 (8), 819-830, 2006

40.       Jain S, Chakraborty G, Bulbule A, Kaur R and Kundu GC: Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin. Ther. Targets 11(1), 81-90, 2007

41.       Rangaswami H, Kundu GC.Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol. Rep. 18 (4):909-15, 2007.

42.       Chakraborty et al. Osteopontin regulated signaling network in cancer: redefining the molecular targets. Intl. J. Mol. Med. 20 (Suppl 1), S75, 2007. 

43.         Chakraborty G, Jain S and Kundu GC: Osteopontin promotes VEGF dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 68 (1), 152-161, 2008.

44.       Chakraborty G, Jain S, Patil TV and Kundu GC: Down-Regulation of Osteopontin Attenuates Breast Tumor Progression in vivo. J. Cell. Mol. Med., 12 (6A), 2305-2318, 2008 .

45.      Chakraborty G, Jain S, Kale S, Raja R, Kumar S, Mishra R and Kundu GC: Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Reports., 1 (5), 641-646, 2008 (selected for cover page).

46.         Jain S, Chakraborty G, Raja R, Kale S, and Kundu GC: Prostaglandin E₂ regulates tumor angiogenesis in prostate cancer. Cancer Res, 68(19):7750–7759, 2008.

47.       Seth D, D'Souza El-Guindy NB, Apte M, Mari M, Dooley S, Neuman M, Haber PS, Kundu GC, Darwanto A, de Villiers WJ, Vonlaufen A, Xu Z, Phillips P, Yang S, Goldstein D, Pirola RM, Wilson JS, Moles A, Fernández A, Colell A, García-Ruiz C, Fernández-Checa JC, Meyer C, Meindl-Beinker NM. Alcohol, Signaling, and ECM Turnover. Alcohol Clin Exp Res. 34 (1), 4-18, 2010.

48.         Behera R, Kumar V, Lohite K, Karnik S and Kundu GC: Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis, 31 (2), 192-200, 2010.

49.          Ahmed M and Kundu GC: Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappa B dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Molecular Cancer 9(1), 101, 2010.

50.          Singh JP, Tamang S, Rajamohanan PR, Jima NC, Chakraborty G, Kundu GC, Gaikwad SM, Khan MI: Isolation, Structure, and Functional Elucidation of a Modified Pentapeptide, Cysteine Protease Inhibitor (CPI-2081) from Streptomyces Species 2081 that Exhibit Inhibitory Effect on Cancer Cell Migration. J. Med Chem, June 16, 2010.

51.       Sharma P, Kumar S and Kundu GC: Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Molecular Cancer, July 7, 9(1), 178, 2010.

52.       Pradhan S, Mishra R, Sharma P and Kundu GC: Quercetin and sulforaphane in combination suppress the melanoma progression through down regulation of matrix metalloproteinase-9. Experimental and Therapeutic Medicine, 1, 915-920, 2010.

53.       Kumar V, Behera R, Lohite K, Karnik S and Kundu GC: p38 Kinase is Crucial for Osteopontin-induced Furin Expression that Supports Cervical Cancer Progression. Cancer Research, 70 (24), 10381-10391, 2010.

54.       Bulbule A, Saraswati Sand Kundu GC: Status of research on matrix metalloproteinases (MMPs) in India. Expert Opin Ther Targets. 2011 Apr 11. [Epub ahead of print]

55.       Prakash M. et al. Hyaluronan-Binding Protein 1 (HABP1/p32/gC1qR) Induces Melanoma Cell Migration and Tumor Growth by NF-kappa B Dependent MMP-2 Activation through integrin αvβ3 interaction. Cellular Signalling. 2011 (in press).

56.       Ahmed et al. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets. 2011 (in press).